(E)-but-2-enedioic acid;propane-1,2,3-triol | 52007-78-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (E)-but-2-enedioic acid;propane-1,2,3-triol
• CAS: 52007-78-0
• 化学式: C7H12O7
• 分子量: 208.17
• InChiKey: VIAMIUDTTIDZCA-TYYBGVCCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.96
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  135
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION
  申请人：K.H.S. Pharma Holding GmbH

  公开号：EP3219309A1

  公开（公告）日：2017-09-20

  The present invention relates to fixed dose pharmaceutical compositions comprising the active substances Candesartan cilexetil, Amlodipine and Hydrochlorothiazide for the treatment of hypertension.

  本发明涉及用于治疗高血压的固定剂量药物组合物，其中包含活性物质坎地沙坦西来替、氨氯地平和氢氯噻嗪。
• FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION.
  申请人：Midas Pharma GmbH

  公开号：EP3429561A1

  公开（公告）日：2019-01-23
• FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION
  申请人：MIDAS PHARMA GMBH

  公开号：US20200289523A1

  公开（公告）日：2020-09-17

  The present invention relates to fixed dose pharmaceutical compositions comprising the active substances Candesartan cilexetil, Amiodipine and Hydrochlorothiazide for the treatment of hypertension.
• [EN] FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION.<br/>[FR] COMPOSITION PHARMACEUTIQUE À DOSES FIXES COMPRENANT DE L'AMIODIPINE, DU CANDÉSARTAN CILEXÉTIL ET DE L'HYDROCHLOROTHIAZIDE POUR LE TRAITEMENT DE L'HYPERTENSION
  申请人：K H S PHARMA HOLDING GMBH

  公开号：WO2017158094A1

  公开（公告）日：2017-09-21

  The present invention relates to fixed dose pharmaceutical compositions comprising the active substances Candesartan cilexetil, Amiodipine and Hydrochlorothiazide for the treatment of hypertension.
• [EN] SOLID ORAL DOSAGE FORM COMPRISING POMALIDOMIDE<br/>[FR] FORME POSOLOGIQUE ORALE SOLIDE COMPRENANT DE LA POMALIDOMIDE
  申请人：TECNIMEDE SOC TECNICO MEDICINAL SA

  公开号：WO2021209919A1

  公开（公告）日：2021-10-21

  The present disclosure relates to the formulation of new pharmaceutical dosage forms of pomalidomide for therapeutic use. The new pharmaceutical dosage forms is an immediate release pharmaceutical composition comprising pomalidomide.